Author

T. Laskowski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:flow cytometry· 2 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Assay:fluorescence / live-cell microscopy· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Lin· 1 shared A. M. Najjar· 1 shared B. Hu· 1 shared D. Mak· 1 shared D. Marin· 1 shared E. Ensley· 1 shared E. Gokdemir· 1 shared E. J. Shpall· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Lin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy

R. Basar, N. Uprety, E. Ensley, M. Daher, K. Klein, F. Martinez, F. Aung, M. Shanley, B. Hu, E. Gokdemir, M. Mendt, F. Reyes Silva, S. Acharya, T. Laskowski, L. Muniz-Feliciano, , K. Rezvani

The paper expands SARS-CoV-2 T-cells from COVID-19 donors using IL-2/4/7 cytokines, achieving >1000-fold expansion with preserved function, and inactivates the glucocorticoid receptor to create glucocorticoid-resistant T-cells for adoptive therapy.

bioRxiv · Sep 15, 2020Immunology

Glucuronoxylomannan in the Cryptococcus species capsule as a target for CAR+ T-cell therapy

T. A. da Silva, P. J. Hauser, I. Bandey, T. Laskowski, Q. Wang, A. M. Najjar, P. Kumaresan

This paper demonstrates that GXMR-CAR+ T cells can effectively target and reduce Cryptococcus neoformans burden in a murine model.

bioRxiv · Jul 26, 2019Immunology